Cellectis Net Receivables vs Total Revenue Analysis

CLLS Stock

USD 2.90 0.02 0.68%

Cellectis financial indicator trend analysis is way more than just evaluating Cellectis SA prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cellectis SA is a good investment. Please check the relationship between Cellectis Net Receivables and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Net Receivables vs Total Revenue

Net Receivables vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cellectis SA Net Receivables account and Total Revenue. At this time, the significance of the direction appears to have weak relationship.

The correlation between Cellectis' Net Receivables and Total Revenue is 0.35. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Cellectis SA, assuming nothing else is changed. The correlation between historical values of Cellectis' Net Receivables and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Cellectis SA are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Net Receivables i.e., Cellectis' Net Receivables and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Receivables

Total Revenue

Total revenue comprises all receipts Cellectis SA generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Cellectis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cellectis SA current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Cellectis' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 389.6 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 50 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	5.3M	3.8M	5.3M	5.6M
Depreciation And Amortization	16.6M	18.4M	18.5M	19.4M

Interest Expense Depreciation And Amortization

Cellectis fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Accounts Payable	Intangible Assets	Current Deferred Revenue	Retained Earnings
Total Assets		0.43	0.27	0.89	0.48	-0.72	0.89	0.34	0.21	0.91	0.29	-0.5	0.79	0.31	0.05	0.8	0.92	0.34	0.4	0.94	-0.5	0.3	0.22	-0.46	0.12	-0.79
Other Current Liab	0.43		0.23	0.24	0.68	-0.03	0.2	0.53	0.08	0.21	0.12	-0.6	0.64	0.47	0.44	0.48	0.6	0.41	0.57	0.26	-0.6	0.51	0.09	-0.61	-0.03	-0.64
Total Current Liabilities	0.27	0.23		-0.07	0.37	0.04	0.15	0.13	0.81	0.23	0.34	-0.4	0.54	0.46	0.78	0.02	0.21	0.85	0.64	0.24	-0.39	0.43	0.02	-0.36	0.93	-0.29
Total Stockholder Equity	0.89	0.24	-0.07		0.12	-0.92	0.95	0.03	-0.12	0.93	0.11	-0.39	0.52	-0.1	-0.31	0.7	0.78	-0.1	-0.01	0.94	-0.4	-0.11	-0.01	-0.39	-0.11	-0.55
Property Plant And Equipment Net	0.48	0.68	0.37	0.12		0.23	0.07	0.92	0.37	0.1	0.42	-0.33	0.68	0.9	0.49	0.56	0.64	0.74	0.93	0.16	-0.33	0.91	0.55	-0.31	0.05	-0.85
Net Debt	-0.72	-0.03	0.04	-0.92	0.23		-0.94	0.36	0.11	-0.92	0.04	0.4	-0.33	0.4	0.38	-0.46	-0.56	0.26	0.29	-0.91	0.41	0.42	0.28	0.4	-0.05	0.24
Cash	0.89	0.2	0.15	0.95	0.07	-0.94		-0.1	0.07	0.99	0.06	-0.5	0.53	-0.08	-0.18	0.65	0.75	0.04	0.02	0.99	-0.5	-0.11	-0.1	-0.48	0.14	-0.5
Non Current Assets Total	0.34	0.53	0.13	0.03	0.92	0.36	-0.1		0.18	-0.07	0.45	-0.01	0.53	0.86	0.33	0.47	0.49	0.58	0.79	-0.01	-0.01	0.88	0.74	0.02	-0.2	-0.72
Non Currrent Assets Other	0.21	0.08	0.81	-0.12	0.37	0.11	0.07	0.18		0.15	0.1	-0.21	0.42	0.51	0.74	0.05	0.16	0.77	0.64	0.15	-0.2	0.46	0.27	-0.22	0.73	-0.33
Cash And Short Term Investments	0.91	0.21	0.23	0.93	0.1	-0.92	0.99	-0.07	0.15		0.1	-0.52	0.6	-0.04	-0.1	0.64	0.76	0.11	0.08	1.0	-0.52	-0.06	-0.09	-0.49	0.22	-0.53
Net Receivables	0.29	0.12	0.34	0.11	0.42	0.04	0.06	0.45	0.1	0.1		-0.03	0.48	0.32	0.15	0.0	0.38	0.38	0.42	0.14	-0.03	0.32	0.34	0.03	0.19	-0.4
Common Stock Total Equity	-0.5	-0.6	-0.4	-0.39	-0.33	0.4	-0.5	-0.01	-0.21	-0.52	-0.03		-0.59	-0.16	-0.21	-0.41	-0.64	-0.32	-0.33	-0.53	1.0	-0.15	0.38	0.94	-0.35	0.5
Common Stock Shares Outstanding	0.79	0.64	0.54	0.52	0.68	-0.33	0.53	0.53	0.42	0.6	0.48	-0.59		0.5	0.48	0.56	0.84	0.61	0.68	0.64	-0.58	0.5	0.22	-0.56	0.32	-0.82
Non Current Liabilities Total	0.31	0.47	0.46	-0.1	0.9	0.4	-0.08	0.86	0.51	-0.04	0.32	-0.16	0.5		0.59	0.44	0.41	0.85	0.92	0.01	-0.15	1.0	0.63	-0.07	0.16	-0.69
Inventory	0.05	0.44	0.78	-0.31	0.49	0.38	-0.18	0.33	0.74	-0.1	0.15	-0.21	0.48	0.59		-0.02	0.09	0.8	0.72	-0.07	-0.2	0.59	0.2	-0.21	0.6	-0.32
Other Current Assets	0.8	0.48	0.02	0.7	0.56	-0.46	0.65	0.47	0.05	0.64	0.0	-0.41	0.56	0.44	-0.02		0.79	0.27	0.42	0.67	-0.41	0.42	0.3	-0.37	-0.16	-0.75
Other Stockholder Equity	0.92	0.6	0.21	0.78	0.64	-0.56	0.75	0.49	0.16	0.76	0.38	-0.64	0.84	0.41	0.09	0.79		0.36	0.52	0.79	-0.64	0.4	0.24	-0.6	0.01	-0.92
Total Liab	0.34	0.41	0.85	-0.1	0.74	0.26	0.04	0.58	0.77	0.11	0.38	-0.32	0.61	0.85	0.8	0.27	0.36		0.91	0.14	-0.31	0.84	0.38	-0.26	0.64	-0.58
Property Plant And Equipment Gross	0.4	0.57	0.64	-0.01	0.93	0.29	0.02	0.79	0.64	0.08	0.42	-0.33	0.68	0.92	0.72	0.42	0.52	0.91		0.13	-0.32	0.91	0.47	-0.32	0.36	-0.77
Total Current Assets	0.94	0.26	0.24	0.94	0.16	-0.91	0.99	-0.01	0.15	1.0	0.14	-0.53	0.64	0.01	-0.07	0.67	0.79	0.14	0.13		-0.53	-0.01	-0.05	-0.5	0.2	-0.57
Common Stock	-0.5	-0.6	-0.39	-0.4	-0.33	0.41	-0.5	-0.01	-0.2	-0.52	-0.03	1.0	-0.58	-0.15	-0.2	-0.41	-0.64	-0.31	-0.32	-0.53		-0.15	0.38	0.94	-0.34	0.5
Short Long Term Debt Total	0.3	0.51	0.43	-0.11	0.91	0.42	-0.11	0.88	0.46	-0.06	0.32	-0.15	0.5	1.0	0.59	0.42	0.4	0.84	0.91	-0.01	-0.15		0.63	-0.07	0.13	-0.69
Accounts Payable	0.22	0.09	0.02	-0.01	0.55	0.28	-0.1	0.74	0.27	-0.09	0.34	0.38	0.22	0.63	0.2	0.3	0.24	0.38	0.47	-0.05	0.38	0.63		0.46	-0.26	-0.44
Intangible Assets	-0.46	-0.61	-0.36	-0.39	-0.31	0.4	-0.48	0.02	-0.22	-0.49	0.03	0.94	-0.56	-0.07	-0.21	-0.37	-0.6	-0.26	-0.32	-0.5	0.94	-0.07	0.46		-0.35	0.46
Current Deferred Revenue	0.12	-0.03	0.93	-0.11	0.05	-0.05	0.14	-0.2	0.73	0.22	0.19	-0.35	0.32	0.16	0.6	-0.16	0.01	0.64	0.36	0.2	-0.34	0.13	-0.26	-0.35		-0.01
Retained Earnings	-0.79	-0.64	-0.29	-0.55	-0.85	0.24	-0.5	-0.72	-0.33	-0.53	-0.4	0.5	-0.82	-0.69	-0.32	-0.75	-0.92	-0.58	-0.77	-0.57	0.5	-0.69	-0.44	0.46	-0.01

Click cells to compare fundamentals

Cellectis Account Relationship Matchups

Cellectis fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	467.5M	469.5M	382.1M	261.2M	334.3M	270.8M
Other Current Liab	12.2M	20.3M	14.6M	28.5M	12.1M	11.9M
Total Current Liabilities	62.6M	52.0M	49.3M	63.0M	155.1M	162.9M
Total Stockholder Equity	315.1M	275.6M	221.3M	118.0M	84.7M	80.5M
Property Plant And Equipment Net	69.3M	145.5M	148.3M	107.9M	92.7M	97.4M
Net Debt	(313.3M)	(156.9M)	(83.9M)	(14.8M)	(43.9M)	(46.0M)
Cash	360.9M	268.2M	186.1M	97.7M	136.7M	183.6M
Non Current Assets Total	75.9M	154.1M	156.6M	117.4M	101.3M	56.0M
Cash And Short Term Investments	360.9M	268.2M	186.1M	97.7M	203.8M	187.9M
Net Receivables	12.1M	15.9M	29.6M	15.3M	23.1M	16.1M
Common Stock Total Equity	2.4M	2.8M	2.8M	2.8M	2.5M	2.4M
Common Stock Shares Outstanding	42.4M	42.5M	44.8M	45.5M	57.0M	33.4M
Liabilities And Stockholders Equity	467.5M	469.5M	382.1M	261.2M	334.3M	270.8M
Non Current Liabilities Total	49.4M	108.6M	96.3M	72.3M	94.4M	99.2M
Inventory	2.9M	1.6M	0.0	21.8M	25.0M	26.3M
Other Current Assets	15.6M	29.6M	9.7M	9.1M	6.1M	8.4M
Other Stockholder Equity	843.5M	863.9M	934.7M	583.1M	522.8M	434.1M
Total Liab	112.0M	160.6M	145.6M	135.3M	249.6M	262.1M
Property Plant And Equipment Gross	69.3M	145.5M	148.3M	107.9M	168.2M	176.6M
Total Current Assets	391.5M	315.4M	225.4M	143.8M	233.0M	214.9M
Accumulated Other Comprehensive Income	(22.6M)	(4.1M)	(18.0M)	(28.6M)	(36.7M)	(38.5M)
Common Stock	2.8M	2.8M	2.9M	3.0M	4.4M	4.1M
Short Long Term Debt Total	47.6M	111.3M	102.2M	82.8M	92.9M	97.5M
Accounts Payable	29.3M	24.6M	23.8M	21.5M	19.1M	18.8M
Intangible Assets	1.1M	1.6M	1.9M	718K	672K	638.4K
Current Deferred Revenue	20.0M	452K	301K	59K	110.3M	115.8M
Retained Earnings	(508.5M)	(587.0M)	(698.3M)	(439.5M)	(405.8M)	(426.1M)
Short Term Debt	1.1M	6.7M	10.7M	13.0M	13.7M	14.3M
Other Assets	1.9M	5.5M	7.0M	6.5M	1.0	0.95
Other Liab	2.9M	8.6M	6.0M	9.4M	10.8M	11.3M
Net Tangible Assets	314.0M	274.0M	219.4M	117.3M	134.8M	243.1M
Long Term Debt	46.5M	28.8M	18.8M	20.5M	28.4M	15.2M
Long Term Investments	5.5M	7.0M	6.5M	8.8M	7.9M	4.1M
Short Long Term Debt	333K	1.1M	2.2M	5.1M	5.2M	5.4M
Property Plant Equipment	69.3M	145.5M	148.3M	107.9M	124.1M	130.3M
Short Term Investments	20.4M	27.1M	499K	7.9M	67.1M	70.5M

Pair Trading with Cellectis

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cellectis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellectis will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cellectis Stock

0.61

DMAC

DiaMedica Therapeutics

Pair Corr

Moving against Cellectis Stock

0.6	IMTXW	Immatics Biotechnologies	Pair Corr
0.6	BMY	Bristol Myers Squibb	Pair Corr
0.53	VRNA	Verona Pharma PLC	Pair Corr
0.5	ELEV	Elevation Oncology	Pair Corr
0.44	VTYX	Ventyx Biosciences	Pair Corr

The ability to find closely correlated positions to Cellectis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cellectis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cellectis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cellectis SA to buy it.

The correlation of Cellectis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cellectis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cellectis SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cellectis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Stock, refer to the following important reports:

How To Invest In Cellectis

Details

Is Cellectis Stock a good investment?

Details

What is Cellectis' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Cellectis Stock analysis

When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.

	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Global Correlations Find global opportunities by holding instruments from different markets

Is Cellectis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectis. If investors know Cellectis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.92)

Revenue Per Share

0.161

Quarterly Revenue Growth

(0.89)

Return On Assets

(0.20)

Return On Equity

(1.11)

The market value of Cellectis SA is measured differently than its book value, which is the value of Cellectis that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectis' value that differs from its market value or its book value, called intrinsic value, which is Cellectis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectis' market value can be influenced by many factors that don't directly affect Cellectis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cellectis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cellectis Net Receivables vs Total Revenue Analysis

Net Receivables vs Total Revenue

Net Receivables vs Total Revenue Correlation Analysis

Correlation Coefficient

Net Receivables

Total Revenue

Cellectis fundamental ratios Correlations

Cellectis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cellectis fundamental ratios Accounts

Pair Trading with Cellectis

Moving together with Cellectis Stock

Moving against Cellectis Stock

Complementary Tools for Cellectis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Cash	+ 0.95	Total Stockholder Equity

Cash	- 0.94	Net Debt
Retained Earnings	- 0.92	Other Stockholder Equity
Cash And Short Term Investments	- 0.92	Net Debt
Net Debt	- 0.92	Total Stockholder Equity
Total Current Assets	- 0.91	Net Debt
Retained Earnings	- 0.85	Property Plant And Equipment Net